LAB PARAMETERS IN PREDICTING SURVIVAL IN PULMONARY ARTERIAL HYPERTENSION

TOPIC: Pulmonary Vascular Disease TYPE: Original Investigations PURPOSE: Lab values are essential sets of parameters for the prognosis patients with pulmonary arterial hypertension (PAH). METHODS: We analyzed lab variables obtained at baseline in 7 PAH clinical trials: SERAPHIN, BREATHE, CHEST-2, PATENT-2, FREEDOM, TRIUMPH, and subcutaneous treprostinil study. The outcome analysis was mortality a time to event each individual trial. selected only significant (p-value<0.05) be aggregated across trials using Stouffer’s method, weighed by their ‘N’ trials. RESULTS: Collective data from 3,387 were available total 45 variables. Out 45, 24 still after aggregation p-values. Elevated Uric acid, leukocyte/neutrophil count, red blood cell neutrophil/lymphocyte ratio, bilirubin (direct & total), AST, BUN most predictive adverse outcomes. Higher Albumin, lymphocyte renal function (Cr, Creatine clearance) improved outcome. CONCLUSIONS: To our knowledge, this is largest attempt analyze predicting survival. This will used select features derivation machine-learned patient risk stratification models CLINICAL IMPLICATIONS: Our long-term goal generate comprehensive personalized assessment tool data-driven variable selections aid decisions. DISCLOSURES: No relevant relationships James Antaki, source=Web Response Grants relationship Actelion Please note: 2019-2021 Added 04/29/2021 Raymond Benza, Response, value=Grant/Research Support Bayer AG Bellerophon EIGER Allen Everett, Advisory Committee Member 2016-2019 04/30/2021 Manreet Kanwar, value=Consulting fee Jidapa Kraisangka, Shili Lin, Zilu Liu, Faezeh Movahedi, Blue Spark Technologies 2020-Present 04/16/2021 Adam Perer, Consultant Johnson 2021-Present Jacqueline Scott,